As filed with the U.S. Securities and Exchange Commission on February 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878-9505 (Addres ...

As filed with the U.S. Securities and Exchange Commission on February 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878- ...

SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on December 3, 2025 (the “December 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding ...

Summary of INVO Fertility FY Conference Call Company Overview - **Company Name**: INVO Fertility - **Ticker Symbol**: IVF (NasdaqCM) - **Industry**: Fertility healthcare - **Business Model**: Operates clinics providing patient care and develops medical devices for fertility treatment, specifically the INVOcell device [3][4] Market Insights - **Market Size**: The U.S. fertility market is estimated to be between $5 billion and $7 billion annually, spread across approximately 460 clinics [4] - **Growth Trends**: The market is experiencing steady growth, but high treatment costs remain a barrier for many potential patients, leading to a significant number of untreated cases each year [4][5] - **Government Initiatives**: Recent policy updates aim to improve affordability, which is expected to increase demand for fertility services [7] Company Growth Strategy Organic Growth - **Key Drivers**: - Increasing outreach programs to boost patient flow - Adding new services and resources to existing clinics - Expanding clinic operations to handle more patient volume [9][10] Acquisition Strategy - **Acquisition Focus**: Acquisitions are a key strategy for near and intermediate-term growth, with a robust pipeline of potential opportunities [11][12] - **Recent Acquisitions**: The company is nearing completion of an acquisition in Indianapolis and has previously acquired a clinic in 2023 [11][12] - **Long-term Growth**: Building new clinics is seen as a significant long-term growth opportunity, with successful examples in Birmingham, Alabama, and Atlanta, Georgia [12] Recent Performance and Initiatives - **Patient Flow Initiatives**: Increased social media presence and targeted advertising are being implemented to attract more patients [15] - **Telehealth Expansion**: Telehealth capabilities have been introduced to improve patient convenience and operational efficiency [17] - **Device Sales Growth**: There has been year-over-year growth in device sales, with renewed focus on training and support for the INVOcell device [19][20] Challenges and Opportunities - **Acquisition Challenges**: While there are many acquisition opportunities, the complexity of closing deals presents a challenge [23] - **Team Expertise**: The company believes it has the necessary expertise to navigate these challenges and meet acquisition objectives for the year [24] Investor Takeaways - **Outlook for 2026**: The company is optimistic about growth prospects, combining organic growth efforts with acquisitions to enhance overall performance [26] - **Positioning**: The management team feels that the company is well-positioned to achieve significant progress and success in 2026 [26]

Company Overview - INVO Fertility, Inc. is a healthcare fertility company focused on establishing, acquiring, and operating fertility clinics and related technologies [3] - The company operates two INVO Centers and one IVF clinic in the United States, and it sells the INVOcell medical device to third-party fertility clinics [3] - INVOcell is a proprietary medical device that allows fertilization and early embryo development to occur in vivo within the woman's body, offering a more intimate and affordable experience compared to traditional ART treatments [3] Upcoming Event - INVO Fertility will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026, at 3:00 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2]

Core Viewpoint - INVO Fertility, Inc. has announced a realignment of its executive leadership team to better support its growth strategy focused on the establishment and acquisition of fertility clinics and related businesses [1][3]. Leadership Changes - Terah Krigsvold has been appointed as the new Chief Financial Officer (CFO), replacing Andrea Goren, who will now serve as Chief Business Officer and CEO of INVO Centers LLC, a subsidiary focused on fertility clinics [2][3]. - The leadership changes are intended to enhance the company's ability to execute its growth plan and achieve profitability [3]. Company Strategy - INVO Fertility is dedicated to expanding access to assisted reproductive technology (ART) and focuses on building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [4]. - The company currently operates two INVO Centers and one IVF clinic in the United States and is involved in the sale and distribution of the INVOcell device to third-party clinics [4]. Product Offering - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more intimate and affordable experience compared to traditional ART treatments [4]. - The IVC procedure enabled by INVOcell is believed to deliver comparable results to traditional IVF at a significantly lower cost and is more effective than intrauterine insemination [4].

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...

Core Viewpoint - INVO Fertility, Inc. has signed a definitive purchase agreement to acquire Family Beginnings, P.C., marking a significant step in its strategy to expand its fertility care centers across the United States [1][2]. Group 1: Acquisition Details - The purchase agreement follows the announcement made on November 27, 2025, regarding the intent to acquire Family Beginnings [2]. - Family Beginnings generated approximately $1.2 million in revenue and $0.2 million in net income for the 12-month period ending September 30, 2025 [2]. - The total purchase price for the acquisition is $750,000, with $350,000 to be paid in cash at closing and $400,000 in preferred stock [4]. Group 2: Strategic Importance - The acquisition aligns with INVO's mission to enhance access to advanced fertility care and expand its operational footprint [3]. - Family Beginnings is recognized for its strong clinical reputation and offers a comprehensive range of reproductive services, including IVF and fertility preservation [3]. Group 3: Leadership and Integration - Dr. James Donahue will continue to lead Family Beginnings under a three-year agreement following the acquisition [4]. - The integration of Family Beginnings into INVO's operations is anticipated to build upon the existing foundation and further grow the practice in the local market [3].

Core Viewpoint - INVO Fertility, Inc. has announced a private placement offering to raise approximately $4.0 million through the sale of common stock and warrants, aimed at expanding its operations in the fertility market [1][2]. Group 1: Offering Details - The company will sell 2,366,864 shares of common stock and warrants to purchase up to 4,733,728 additional shares, with a combined effective offering price of $1.69 per share [1]. - The warrants will have an exercise price of $1.69 per share, exercisable upon shareholder approval, and will expire five years from the date of such approval [1]. - The offering is expected to close on or about December 3, 2025, pending customary closing conditions [2]. Group 2: Financial Implications - Gross proceeds from the offering are estimated to be approximately $4.0 million before deducting fees and expenses related to the placement [2]. - Maxim Group LLC is acting as the sole placement agent for this offering [2]. Group 3: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell technology [5]. - The company operates two INVO Centers and one IVF clinic in the United States, offering the intravaginal culture (IVC) procedure, which is designed to provide a more natural and cost-effective alternative to traditional IVF [5]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, potentially delivering comparable results to traditional methods at a lower cost [5].